Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Zhang, De Qing ^a   Guo, Qiang ^a   Zhu, Jian Hong ^a   Chen, Wei Chang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Apoptosis; Celecoxib; Colorectal cancer

Indexed keywords

CASPASE 3; CASPASE 9; CELECOXIB; CYTOCHROME C; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ELECTRON MICROSCOPY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROMES C; FLUOROURACIL; HT29 CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRAZOLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872677638     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-16     Document Type: Article

References (28)

1. Debatin K. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 2000, 112:41-48.
2. Iwaizumi M, Tseng-Rogenski S, Carethers JM. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther 2011, 15:756-764.
3. Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, Saini JP, Gilberg F, Cunningham D. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol 2011, 22:2604-2609. 10.1093/annonc/mdr031, 21415237.
4. Kodama Y, Fumoto S, Nishi J, Nakashima M, Sasaki H, Nakamura J, Nishida K. Absorption and distribution characteristics of 5-fluorouracil (5-FU) after an application to the liver surface in rats in order to reduce systemic side effects. Biol Pharm Bull 2008, 31:1049-1052. 10.1248/bpb.31.1049, 18451546.
5. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 2006, 12:1336-1345.
6. Sade A, Tunçay S, Çimen T, Severcan F, Banerjee S. Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. Biosci Rep 2012, 32:35-44. 10.1042/BSR20100149, 21401528.
7. Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 2008, 47:519-525. 10.1002/mc.20409, 18163459.
8. Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 2011, 12:1888-1894. 10.2174/138945011798184218, 21158711.
9. Lim YJ, Rhee JC, Bae YM, Chun WJ. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J Gastroenterol 2007, 13:1947-1952.
10. Lrie T, Tsujii M, Tsuji S. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN- γ. Int J Cancer 2007, 121:878-883. 10.1002/ijc.22720, 17450522.
11. Debucquoy A, Roels S, Goethals L, Libbrecht L, Van Cutsem E, Geboes K, Penninckx F, D'Hoore A, McBride WH, Haustermans K. Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer. Radiother Oncol 2009, 93:273-278. 10.1016/j.radonc.2009.08.006, 19747744.
12. Krajewska M, Krajewski S, Epstein JI. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996, 148:1567-1576. 1861561, 8623925.
13. Qi X, Chen Z, Liu D, Cen J, Gu M. Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells. Int J Mol Med 2008, 22:61-68.
14. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:4954-4962. 10.1158/1078-0432.CCR-08-3317, 19622584.
15. Toomey D, Conroy H, Jarnicki AG, Higgins SC, Sutton C, Mills KH. Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine 2008, 26:3540-3549. 10.1016/j.vaccine.2008.04.005, 18479787.
16. Bocca C, Bozzo F, Bassignana A, Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011, 26:59-70.
17. Yan YX, Li WZ, Huang YQ, Liao WX. The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function. Prostaglandins Other Lipid Mediat 2012, 97:29-35. 10.1016/j.prostaglandins.2011.07.007, 21835258.
18. Schwartz JI, Dallob AL, Larson PJ, Laterza OF, Miller J, Royalty J, Snyder KM, Chappell DL, Hilliard DA, Flynn ME, Cavanaugh PF, Wagner JA, Hegazy R, Alashhab M, Amin M. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008, 48:745-754. 10.1177/0091270008317590, 18434566.
19. Rao PN, Grover RK. Apricoxib: a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs 2009, 12:711-722.
20. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007, 37:681-690. 10.1165/rcmb.2007-0051OC, 17600315.
21. Liu B, Qu L, Tao H. Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol Int 2010, 34:21-25.
22. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol 2011, 34:581-586. 10.1097/COC.0b013e3181fe46a1, 3133812, 21217396.
23. Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, Chen G. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 2012, 23:1348-1353. 10.1093/annonc/mdr400, 21940785.
24. El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 2008, 61:283-289.
25. Jin CH, Wang AH, Chen JM, Li RX, Liu XM, Wang GP, Xing LQ. Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. J Int Med Res 2011, 39:2129-2140.
26. Unger KR, Romney DA, Koc M, Moskaluk CA, Friel CM, Foley EF, Rich TA. Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. Int J Radiat Oncol Biol Phys 2011, 80:1377-1382. 10.1016/j.ijrobp.2010.04.016, 20656421.
27. Wang F, Sun GP, Zou YF, Wu Q, Wu HY, Wu JF, Zhou JD, Chen K, Zhang XS. Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma:correlations with clinicopathologic features. Folia Histochem Cytobiol 2011, 49:389-397.
28. Borrego JF, Cartagena JC, Engel J. Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases. Vet Comp Oncol 2009, 7:213-221. 10.1111/j.1476-5829.2009.00194.x, 19891691.